1. FRI0446 Prevalence and characteristics of spondyloarthritis according to asas criteria in patients with inflammatory bowel disease – results from the spice cohort. (15th June 2017) Authors: Haschka, J; Hirschmann, S; Kleyer, A; Englbrecht, M; Zimmermann, J; Faustini, F; Simon, D; Figueiredo, CP; Cavallaro, A; Muschitz, C; Kocijan, R; Resch, H; Atreya, R; Rech, J; Neurath, MF; Schett, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients. (16th January 2018) Authors: Fischer, S; Klenske, E; Schmitt, H; Vitali, F; Hirschmann, S; Koch, F; Ramming, A; Zundler, S; Nagore, D; Uter, W; Neurath, M F; Atreya, R Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P763 Addiction in IBD patients: more than just smoke?. (25th January 2019) Authors: Hirschmann, S; Koehnen, J; Schuster, B; Atreya, R; Krauss, N; Mudter, J; Dauer, M; Hagel, A; Neurath, M F; Albrecht, H Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S502 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗